New combo therapy aims to stall lung cancer progression
NCT ID NCT04743505
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests whether adding the experimental drug APL-101 to the standard treatment osimertinib can help control EGFR-mutated non-small cell lung cancer that has spread. About 27 adults with advanced lung cancer who have already started osimertinib will receive the combination until their disease worsens. The goal is to find the safest dose and see if it delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.